ABT vs ALGN vs SOLV Stock Comparison

Abbott Laboratories, Align Technology and Solventum Prices as of Nov 13, 2026 Peers: Industry group
ABT Abbott Laboratories
$108.54 +5.4% 1M -16.0% 1Y
Market cap
$188.03B
P/E
40.0x
Revenue (TTM)
$48.23B
Div. yield
0.02%
Medical Devices Healthcare
6 wins
ALGN Align Technology Inc
$168.32 +16.5% 1M +20.7% 1Y
Market cap
$11.84B
P/E
24.1x
Revenue (TTM)
$4.16B
Div. yield
–
Dental Healthcare
4 wins
SOLV Solventum Corp
$89.05 +2.0% 1M +18.4% 1Y
Market cap
$15.28B
P/E
98.0x
Revenue (TTM)
$8.16B
Div. yield
–
Medical Devices Healthcare
1 win

Head to Head

11 decided of 12

Abbott Laboratories leads on 6 of the 12 questions below (Abbott Laboratories 6, Align Technology 4, Solventum 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABTALGNSOLVLeader
Larger companyMarket capitalisation $188.03B $11.84B $15.28B ABT
Cheaper on earningsLower P/E, profitable companies only 40.0x 24.1x 98.0x ALGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 19.1x 15.5x 12.8x SOLV
Faster revenue growthRevenue growth, trailing twelve months +10.0% +4.4% -2.8% ABT
More profitableNet margin, trailing twelve months 9.7% 11.8% 1.9% ALGN
Better return on capitalReturn on invested capital 5.7% — 4.2% ABT
Less leveragedLower net debt / EBITDA 2.5x — 4.7x ABT
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -16.0% +20.7% +18.4% ALGN
Better 5-year returnAnnualised price return, 5 years -3.3%/yr -24.6%/yr — ABT
Less volatileAnnualised volatility, 1 year 28.5% 40.3% 30.1% ABT
Higher overall scoreMean of the five percentile scores vs peers 56/100 70/100 51/100 ALGN

Percentile Scorecard

ABTALGNSOLV

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABTALGNSOLV
Valuation 74 #65 of 243 85 #37 of 243 70 #74 of 243
Growth 26 #168 of 228 38 #142 of 228 3 #221 of 228
Profitability 82 #41 of 222 87 #29 of 222 71 #66 of 222
Financial Health 33 #167 of 248 48 #130 of 248 15 #210 of 248
Shareholder Returns 65 #56 of 158 92 #13 of 158 94 #10 of 158
Overall 56 70 51
  • ABT ranked among 252 companies in Medical Devices and Diagnostics
  • ALGN ranked among 252 companies in Medical Devices and Diagnostics
  • SOLV ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABTALGNSOLVSPY
1 month +5.4%+16.5%+2.0% -2.0%
3 months -2.4%-7.2%+0.5% -2.8%
6 months +28.5%+7.0%+19.9% +2.0%
Year to date -13.4%+7.8%+12.4% +10.6%
1 year -16.0%+20.7%+18.4% +12.2%
3 years +11.8%-17.0%— +68.1%
3 years, per year +3.8%-6.0%— +18.9%
5 years -15.5%-75.5%— +61.4%
5 years, per year -3.3%-24.6%— +10.1%
10 years +170.4%+83.9%— +248.5%
10 years, per year +10.5%+6.3%— +13.3%

Risk

MeasureABTALGNSOLVSPY
Volatility, 1Y 28.5%40.3%30.1% 13.6%
Downside volatility, 1Y 27.8%37.6%29.3% 13.9%
Beta vs S&P 500, 1Y 0.071.330.61 1.00
Return / volatility, 1Y -0.560.510.61 0.90
Max drawdown, 5Y -41.6%-82.0%-40.0% -25.4%
From 52-week high -16.9%-14.8%-3.7% -3.2%
52-week high $130.59$197.51$92.45 $779.14
52-week low $82.56$132.28$62.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABTALGNSOLV
P/E now vs peer median 40.0xmedian 26.5x 24.3xmedian 26.5x 97.5xmedian 26.5x
P/S now vs peer median 3.9xmedian 2.7x 2.9xmedian 2.7x 1.9xmedian 2.7x
EV/EBITDA now vs peer median 20.3xmedian 18.4x 12.5xmedian 18.4x 20.3xmedian 18.4x
P/FCF now vs peer median 27.8xmedian 25.4x 19.7xmedian 25.4x 156.0xmedian 25.4x
P/B now vs peer median 3.6xmedian 2.5x 2.8xmedian 2.5x 3.1xmedian 2.5x
PEG now vs peer median -13.92median 0.98 1.78median 0.98 —median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABTALGNSOLV
Revenue $48.23B $4.16B $8.16B
Gross profit $27.46B $2.88B $4.47B
Operating income $6.65B $620.46M $454.00M
Net income $4.70B $491.87M $156.00M
Free cash flow $6.76B $602.50M –
R&D $3.31B $377.60M $723.00M
EPS (diluted) $2.70 $6.93 $0.91
Cash & equivalents $4.05B $1.14B $451.00M
Total debt $31.16B – $5.07B
Shares (diluted) 1.74B 71.02M 170.80M
Enterprise value $161.90B $7.44B $12.99B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABTALGNSOLV
P/E 40.0x 24.3x 97.5x
P/FCF 27.8x 19.7x 156.0x
P/Operating cash flow 21.2x 15.9x 48.8x
P/S 3.9x 2.9x 1.9x
P/B 3.6x 2.8x 3.1x
P/Tangible book 5.9x 2.8x 6.1x
EV/EBITDA 20.3x 12.5x 20.3x
EV/EBIT 32.3x 17.3x 43.5x
EV/Revenue 4.5x 2.6x 2.4x
EV/FCF 31.8x 17.8x –
EV/Operating cash flow 24.3x 14.3x 63.7x
PEG (3Y EPS CAGR) -13.92 1.78 –

Growth

14 metrics
MetricABTALGNSOLV
Revenue growth (1Y) 10.0% 4.4% -2.8%
Revenue CAGR (3Y) 6.5% 3.0% –
Gross profit growth (1Y) 12.1% 5.5% -1.6%
Gross profit CAGR (3Y) 7.8% 2.7% –
Operating income growth (1Y) -13.8% 16.1% -79.3%
Operating income CAGR (3Y) 3.5% 2.0% –
Net income growth (1Y) -66.4% 30.0% -89.8%
Net income CAGR (3Y) -3.1% 10.7% –
EPS growth (1Y) -66.1% 32.6% -89.5%
EPS CAGR (3Y) -2.9% 13.6% –
Operating cash flow growth (1Y) -2.9% 14.3% -37.1%
Operating cash flow CAGR (3Y) 10.6% -5.3% –
Free cash flow growth (1Y) -2.3% 6.3% –
Free cash flow CAGR (3Y) 14.6% -4.2% –

Profitability

14 metrics
MetricABTALGNSOLV
Gross margin 56.9% 69.1% 54.8%
EBITDA margin 21.9% 20.6% 11.9%
Operating margin 13.8% 14.9% 5.6%
Pretax margin 13.6% 15.5% 2.1%
Net margin 9.7% 11.8% 1.9%
FCF margin 14.0% 14.5% –
Operating cash flow margin 18.4% 18.0% 3.8%
Return on equity 9.1% 11.5% 3.3%
Return on assets 4.3% 7.6% 1.1%
Return on invested capital 5.7% – 4.2%
Return on capital employed 7.2% 13.6% 4.3%
Asset turnover 0.4x 0.6x 0.6x
Cash conversion (OCF / net income) 1.9x 1.5x 2.0x
Stock comp / revenue 1.5% 4.1% 2.1%

Financial Health

11 metrics
MetricABTALGNSOLV
Debt / assets 28.8% – 35.8%
Debt / equity 0.6x – 1.1x
Net debt / EBITDA 2.5x – 4.7x
Debt / FCF 4.6x – –
Liabilities / assets 52.3% 34.0% 66.1%
Equity / assets 47.7% 66.0% 33.9%
Interest coverage 6.7x – –
Current ratio 1.5x 1.4x 1.0x
Quick ratio 0.8x 1.2x 0.5x
Cash ratio 0.3x 0.6x 0.1x
Altman Z-score 3.36 4.89 1.85

Shareholder Returns

7 metrics
MetricABTALGNSOLV
Dividend yield 2.3% – –
Net buyback yield 0.7% 2.3% 2.7%
Shareholder yield 3.0% 2.3% 2.7%
Payout ratio (earnings) 92.0% – –
Payout ratio (FCF) 64.0% – –
Dividend growth (1Y) 6.9% – –
Dividend CAGR (3Y) 7.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABTALGNSOLV
Forward P/E 19.1xFY2026 15.5xFY2026 12.8xFY2026
EPS, next fiscal year $5.69FY2026 $10.86FY2026 $6.93FY2026
EPS growth, next FY +10.5%FY2026 +3.3%FY2026 +13.4%FY2026
EPS growth, the year after +10.2% +16.6% +15.3%
Revenue, next fiscal year $52.99BFY2026 $3.84BFY2026 $7.71BFY2026
Revenue growth, next FY +19.5%FY2026 -4.7%FY2026 -7.3%FY2026
Revenue growth, the year after -2.3% +3.1% +5.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABTALGNSOLV
Held by institutions 79.2% 100.0% 73.9%
Institutions holding 2,983 678 882
Change in shares held, QoQ +0.3% +4.2% -0.9%
Institutions buying 1,261 293 370
Institutions selling 1,379 268 286
Buyers to sellers 0.91 1.09 1.29

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABTALGNSOLV
ABT 1.00 0.24 0.37
ALGN 0.24 1.00 0.53
SOLV 0.37 0.53 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ABT, ALGN and SOLV?

Abbott Laboratories (ABT) is the largest by market capitalisation: Abbott Laboratories (ABT) $188.03B, Align Technology (ALGN) $11.84B, Solventum (SOLV) $15.28B.

Which stock is cheaper, ABT, ALGN and SOLV?

Align Technology (ALGN) trades on the lowest price-to-earnings ratio (Abbott Laboratories (ABT) 40.0x, Align Technology (ALGN) 24.1x, Solventum (SOLV) 98.0x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Abbott Laboratories (ABT) 19.1x, Align Technology (ALGN) 15.5x, Solventum (SOLV) 12.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Abbott Laboratories (ABT) grew revenue fastest over the trailing twelve months: Abbott Laboratories (ABT) +10.0%, Align Technology (ALGN) +4.4%, Solventum (SOLV) -2.8%.

Which company is more profitable?

Align Technology (ALGN) has the highest net margin (Abbott Laboratories (ABT) 9.7%, Align Technology (ALGN) 11.8%, Solventum (SOLV) 1.9%). On return on invested capital, Abbott Laboratories (ABT) leads (Abbott Laboratories (ABT) 5.7%, Solventum (SOLV) 4.2%).

Which stock has performed better?

Over the past year Align Technology (ALGN) returned the most: Abbott Laboratories (ABT) -16.0%, Align Technology (ALGN) +20.7%, Solventum (SOLV) +18.4%. Over five years, Abbott Laboratories (ABT) compounded fastest (Abbott Laboratories (ABT) -3.3%/yr, Align Technology (ALGN) -24.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Abbott Laboratories (ABT) 0.02%, Align Technology (ALGN) 0.00%, Solventum (SOLV) 0.00%. Align Technology (ALGN) and Solventum (SOLV) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Abbott Laboratories (ABT) has been the steadiest (Abbott Laboratories (ABT) 28.5%, Align Technology (ALGN) 40.3%, Solventum (SOLV) 30.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ABT, ALGN and SOLV?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Abbott Laboratories (ABT) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.